Managing immune checkpoint-blocking antibody side effects.

  title={Managing immune checkpoint-blocking antibody side effects.},
  author={Michael A Postow},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
Immune checkpoint-blocking antibodies that enhance the immune system's ability to fight cancer are becoming important components of treatment for patients with a variety of malignancies. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) was the first immune checkpoint to be clinically targeted, and ipilimumab, an inhibitor of CTLA-4, was approved by the U.S. Food and Drug Administration (FDA) for patients with advanced melanoma. The programmed cell death-1 (PD-1) receptor and one of its… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 82 extracted citations

Supportive care for patients undergoing immunotherapy

Supportive Care in Cancer • 2017
View 4 Excerpts
Highly Influenced

Immune-Related Adverse Events From Immune Checkpoint Inhibitors.

Clinical pharmacology and therapeutics • 2016
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…